Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature

被引:23
作者
Bortolati, Maria [1 ]
Marson, Piero [2 ]
Fabris, Fabrizio [3 ]
Pengo, Vittorio [4 ]
Facchinetti, Myriam [1 ]
De Silvestro, Giustina [2 ]
Ruffatti, Amelia [1 ]
机构
[1] Univ Padua, Rheumatol Unit, Dept Clin & Expt Med, Padua, Italy
[2] Univ Hosp Padua, Blood Transfus Serv, Apheresis Unit, Padua, Italy
[3] Univ Padua, Dept Med & Surg Sci, Padua, Italy
[4] Univ Padua, Thrombosis Ctr, Dept Cardiothorac & Vasc Sci, Padua, Italy
关键词
Catastrophic Antiphospholipid Syndrome; Plasma exchange; Replacement fluid; THERAPEUTIC APHERESIS; PROGNOSTIC-FACTORS; PREVENTING DEATH; PATIENT; ANTICOAGULATION; ANTIBODIES; PLASMAPHERESIS; HYPERTENSION; GUIDELINES; MANAGEMENT;
D O I
10.1016/j.autrev.2008.09.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Catastrophic Anti phospholipid Syndrome (CAPS) is a rare (1%), life-threatening variant of Antiphospholipid Syndrome (APS). It has been found that the recovery rate is best when the treatment protocol includes anticoagulants, steroids and therapeutic plasma exchange (TPE). The treatment of CAPS with TPE is not, however, well defined as procedure modalities have not yet been standardized, and the best replacement fluid for TPE is still a controversial issue. Although the most commonly used one, fresh frozen plasma (FFP), contains natural anticoagulants, it is also made up of clotting factors, complement activation products and cytokines which could worsen CAPS' "thrombotic storm". The successful management of 4 CAPS patients, including TPE sessions initiated in the 1st week from diagnosis and using albumin solution as the replacement fluid, is described here. TPE was performed daily for the first 3 days. then tapered off, and withdrawn on the basis of patient's clinical condition. One of the patients was also treated with anticoagulants, while the others received anticoagulants plus high doses of steroids in addition to TPE. Our results indicate that, when initiated promptly and albumin solution is used as the replacement fluid, TPE can be considered an effective, safe treatment for CAPS. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:297 / 301
页数:5
相关论文
共 34 条
[1]   Catastrophic antiphospholipid syndrome -: Clinical and laboratory features of 50 patients [J].
Asherson, RA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Lie, JT ;
Burcoglu, A ;
Lim, K ;
Muñoz-Rodríguez, FJ ;
Levy, RA ;
Boué, F ;
Rossert, J ;
Ingelmo, M .
MEDICINE, 1998, 77 (03) :195-207
[2]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[3]   Catastrophic antiphospholipid syndrome -: Clues to the pathogenesis from a series of 80 patients [J].
Asherson, RA ;
Cervera, R ;
Piette, JC ;
Shoenfeld, Y ;
Espinosa, G ;
Petri, MA ;
Lim, E ;
Lau, TC ;
Gurjal, A ;
Jedryka-Góral, A ;
Chwalinska-Sadowska, H ;
Dibner, RJ ;
Rojas-Rodriguez, J ;
Garcia-Carrasco, M ;
Grandone, JT ;
Parke, AL ;
Barbosa, P ;
Vasconcelos, C ;
Ramos-Casals, M ;
Font, J ;
Ingelmo, M .
MEDICINE, 2001, 80 (06) :355-377
[4]   New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS") [J].
Asherson, Ronald A. .
AUTOIMMUNITY REVIEWS, 2006, 6 (02) :76-80
[5]   Mortality in the catastrophic antiphospholipid syndrome:: Causes of death and prognostic factors [J].
Bucciarelli, Silvia ;
Cervera, Ricard ;
Espinosa, Gerard ;
Gomez-Puerta, Jose A. ;
Ramos-Casals, Manuel ;
Font, Josep .
AUTOIMMUNITY REVIEWS, 2006, 6 (02) :72-75
[6]   Mortality in the catastrophic antiphospholipid syndrome - Causes of death and prognostic factors in a series of 250 patients [J].
Bucciarelli, Silvia ;
Espinosa, Gerard ;
Cervera, Ricard ;
Erkan, Doruk ;
Gomez-Puerta, Jose A. ;
Ramos-Casals, Manuel ;
Font, Josep ;
Asherson, Ronald A. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2568-2576
[7]   Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Shoenfeld, Y ;
Camps, MT ;
Jacobsen, S ;
Lakos, G ;
Tincani, A ;
Kontopoulou-Griva, I ;
Galeazzi, M ;
Meroni, PL ;
Derksen, RHWM ;
de Groot, PG ;
Gromnica-Ihle, E ;
Baleva, M ;
Mosca, M ;
Bombardieri, S ;
Houssiau, F ;
Gris, JC ;
Quéré, I ;
Hachulla, E ;
Vasconcelos, C ;
Roch, B ;
Fernández-Nebro, A ;
Boffa, MC ;
Hughes, GRV ;
Ingelmo, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027
[8]   Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry [J].
Cervera, Ricard ;
Espinosa, Gerard ;
Bucciarelli, Silvia ;
Gomez-Puerta, Jose A. ;
Font, Josep .
AUTOIMMUNITY REVIEWS, 2006, 6 (02) :81-84
[9]  
Elchalal U, 2006, ISRAEL MED ASSOC J, V8, P856
[10]   Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome [J].
Erkan, Doruk .
AUTOIMMUNITY REVIEWS, 2006, 6 (02) :98-103